Insider Buying Signals Confidence in Agenus’s Immuno‑Oncology Growth Path
Insider buying fuels optimism for Agenus’s TCR therapy and bispecific platform, highlighting potential growth amid FDA milestones and partnership upside.
5 minutes to read
Agenus Inc
CEO Insider Buying at Agenus Boosts Investor Confidence & Sparks Short‑Term Rally
CEO insider buys 4,829 Agenus shares, signaling confidence in the company’s immuno‑oncology pipeline and potential upside for investors.
3 minutes to read
Inside Agenus: Insider Confidence Fuels Strategic Zydus Deal
Discover how Agenus insider moves and a $141 M partnership with Zydus could shift its stock outlook amid earnings pressure.
3 minutes to read